(-0.13%) 5 461.93 points
(-0.35%) 38 975 points
(0.22%) 17 756 points
(0.31%) $81.08
(-3.48%) $2.66
(-0.89%) $2 310.00
(-0.29%) $28.79
(1.46%) $1 000.80
(0.29%) $0.936
(0.78%) $10.69
(0.42%) $0.792
(-0.76%) $86.83
Live Chart Being Loaded With Signals
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics...
Stats | |
---|---|
本日の出来高 | 50 356 |
平均出来高 | 0 |
時価総額 | 52.26M |
EPS | $-0.0863 ( Q1 | 2024-05-08 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
0 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-11-28 | Desai Arjun Jj | Buy | 33 040 | Stock Options (Right to buy) |
2023-11-28 | Jacobovitz Shalom | Buy | 42 736 | Stock Options (Right to buy) |
2023-11-28 | Matlin David J | Buy | 56 024 | Stock Options (Right to buy) |
2023-11-28 | Kiernan Matthew | Buy | 28 730 | Stock Options (Right to buy) |
2023-11-28 | Mosca Alison | Buy | 43 814 | Stock Options (Right to buy) |
INSIDER POWER |
---|
99.46 |
Last 99 transactions |
Buy: 47 544 964 | Sell: 666 194 |
Clene Inc. 財務諸表
Annual | 2023 |
収益: | $654 000 |
総利益: | $-1.17M (-179.20 %) |
EPS: | $-0.470 |
FY | 2023 |
収益: | $654 000 |
総利益: | $-1.17M (-179.20 %) |
EPS: | $-0.470 |
FY | 2022 |
収益: | $473 000 |
総利益: | $447 000 (94.50 %) |
EPS: | $-0.230 |
FY | 2021 |
収益: | $723 000 |
総利益: | $434 000 (60.03 %) |
EPS: | $0 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Clene Inc.
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain\'s energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson\'s Diseases. The company\'s products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。